Biotech’s comeback looks built to last
The Wall Street Journal - 13-Oct-2025Easing regulations and new drug approvals fuel optimism for a sustained biotech rally
The Live Forever Club is evolving. Subscribe to the newsletter to be the first to hear about this important change.
Columnist for The Wall Street Journal
David Wainer is a Brazilian-American columnist based in New York who writes for the “Heard on the Street” section of The Wall Street Journal, with a primary focus on the business of healthcare, biotech and pharmaceuticals. He holds a bachelor’s degree in finance and brings together financial market insight and health-industry analysis, regularly exploring topics such as insurance trends, drug-maker strategies and longevity science.
Visit website: https://www.wsj.com/news/author/david-wainer
See alsoDetails last updated 05-Nov-2025
Easing regulations and new drug approvals fuel optimism for a sustained biotech rally
Easing regulations and new drug approvals fuel optimism for a sustained biotech rally